| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2017.74.5471 |
| P698 | PubMed publication ID | 29095678 |
| P50 | author | Sarina Piha-Paul | Q56890176 |
| Jean-Sébastien Frénel | Q58259189 | ||
| Hope Rugo | Q55975497 | ||
| P2093 | author name string | Christophe Le Tourneau | |
| Reshma Rangwala | |||
| Andrea Varga | |||
| Carlos Gomez-Roca | |||
| Patrick A Ott | |||
| Emilie M J van Brummelen | |||
| Sanatan Saraf | |||
| Shari Thomas | |||
| Bert O'Neil | |||
| P433 | issue | 36 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cervix uterine cancer | Q160105 |
| pembrolizumab | Q13896859 | ||
| P304 | page(s) | 4035-4041 | |
| P577 | publication date | 2017-11-02 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial | |
| P478 | volume | 35 |
| Q61807226 | -mutated clear cell cervical cancer associated with in-utero diethylstilbestrol exposure |
| Q90292730 | A Case of Nivolumab-Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein-1/Programmed Death Ligand-1 Inhibitors and Recommendations for Diagnosis and Management |
| Q56515605 | A Phase I Evaluation of Extended Field Radiation Therapy With Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women With Cervical Carcinoma Metastatic to the Para-aortic Lymph Nodes: An NRG Oncology/Gynecolog |
| Q90287047 | A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus-associated Epithelial Cancers |
| Q92016091 | A systematic analysis of immune genes and overall survival in cancer patients |
| Q100762157 | Baseline immunity and impact of chemotherapy on immune microenvironment in cervical cancer |
| Q52570998 | Bevacizumab with metronomic chemotherapy of low-dose oral cyclophosphamide in recurrent cervical cancer: Four cases. |
| Q52582301 | Cervical cancer - State of the science: From angiogenesis blockade to checkpoint inhibition. |
| Q90953584 | Cervical cancer patients that respond to chemoradiation therapy display an intense tumor infiltrating immune profile before treatment |
| Q64914511 | Clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome. |
| Q90354145 | Clinical study of nimotuzumab combined with concurrent radiochemotherapy for treatment of locally advanced cervical cancer |
| Q64983989 | Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data. |
| Q59808385 | Combination Immune Checkpoint Blockade Strategies to Maximize Immune Response in Gynecological Cancers |
| Q91906078 | Completely resolved advanced biliary tract cancer after treatment by pembrolizumab: a report of two cases |
| Q56890243 | Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors |
| Q93335065 | Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade |
| Q92202201 | Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: Multicenter, open-label phase 2 trial |
| Q64239710 | Efficacy of PD-1 blockade in cervical cancer is related to a CD8FoxP3CD25 T-cell subset with operational effector functions despite high immune checkpoint levels |
| Q98164819 | Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials |
| Q99552004 | Endoscopical and pathological dissociation in severe colitis induced by immune-checkpoint inhibitors |
| Q92562854 | Evidence-Based Treatment Paradigms for Management of Invasive Cervical Carcinoma |
| Q59329233 | Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium |
| Q57072711 | Gene Expression Analysis Identifies Novel Targets for Cervical Cancer Therapy |
| Q97645835 | High-Risk HPV Oncoproteins and PD-1/PD-L1 Interplay in Human Cervical Cancer: Recent Evidence and Future Directions |
| Q92285498 | Immune checkpoint expression, microsatellite instability, and mutational burden: Identifying immune biomarker phenotypes in uterine cancer |
| Q92638791 | Immune checkpoint inhibitors in the treatment of virus-associated cancers |
| Q90164090 | Immunotherapy for Uterine Cervical Cancer |
| Q90642659 | LOXL2 Expression Status Is Correlated With Molecular Characterizations of Cervical Carcinoma and Associated With Poor Cancer Survival via Epithelial-Mesenchymal Transition (EMT) Phenotype |
| Q90091962 | Looking past PD-L1: expression of immune checkpoint TIM-3 and its ligand galectin-9 in cervical and vulvar squamous neoplasia |
| Q54952356 | Major clinical research advances in gynecologic cancer in 2017. |
| Q90702080 | Moving Forward in Cervical Cancer - Enhancing Susceptibility to DNA Repair Inhibition and Damage: NCI Clinical Trials Planning Meeting Report |
| Q98158105 | Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial |
| Q64104791 | Next generation sequencing driven successful combined treatment with laparoscopic surgery and immunotherapy for relapsed stage IVB cervical and synchronous stage IV lung cancer |
| Q92363011 | Novel Delivery Systems for Checkpoint Inhibitors |
| Q61803811 | PD-1/PD-L1 Inhibitors in Cervical Cancer |
| Q59357945 | PD-1/PD-L1 immune checkpoint inhibitors in advanced cervical cancer |
| Q92705771 | Phase I Study of a B Cell-Based and Monocyte-Based Immunotherapeutic Vaccine, BVAC-C in Human Papillomavirus Type 16- or 18-Positive Recurrent Cervical Cancer |
| Q92560472 | Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002) |
| Q89450684 | Preface: More than two decades of modern tumor immunology |
| Q91284516 | Preface: More than two decades of modern tumor immunology |
| Q95591987 | Preface: More than two decades of modern tumor immunology |
| Q99714486 | Real-World Experience with Pembrolizumab Treatment in Patients with Heavily Treated Recurrent Gynecologic Malignancies |
| Q64108445 | Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer |
| Q90642504 | Risk of Gastrointestinal Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitor Plus Chemotherapy: A Systematic Review and Meta-Analysis |
| Q88654117 | Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study |
| Q92708769 | TIM-3 in endometrial carcinomas: an immunotherapeutic target expressed by mismatch repair-deficient and intact cancers |
| Q98164379 | Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence |
| Q58609934 | The Role of PD-1 Checkpoint Inhibition in Gynecologic Malignancies |
| Q64256609 | The Tolerogenic Function of Regulatory T Cells in Pregnancy and Cancer |
| Q58608193 | Time to abandon single-site irradiation for inducing abscopal effects |
| Q90300273 | Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis |
| Q55386599 | Tumor molecular profiling of responders and non-responders following pembrolizumab monotherapy in chemotherapy resistant advanced cervical cancer. |
| Q98946863 | Uncovering PD-L1 and CD8+ TILS Expression and Clinical Implication in Cervical Squamous Cell Carcinoma |
| Q102053029 | Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity |
| Q98503965 | Vaginal microbiota, genital inflammation, and neoplasia impact immune checkpoint protein profiles in the cervicovaginal microenvironment |
Search more.